Magenta Therapeutics develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy.
Market Cap | 38.81 Million | Shares Outstanding | 60.64 Million | Avg 30-day Volume | 969.577 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.29 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -72.672 Million |
Price to Book Value | 1.4097 | Operating Margin | 0.0 | Enterprise Value | 66.497 Million |
Current Ratio | 16.634 | EPS Growth | 0.246 | Quick Ratio | 16.287 |
1 Yr BETA | 0.697 | 52-week High/Low | 2.24 / 0.32 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 7.0162 | Altman Z-Score | 5.8365 | Free Cash Flow to Firm | -52.959 Million |
Earnings Report | 2023-08-03 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
3,058,204 | 2023-02-07 | 1 | |
GARDNER JASON SEE REMARKS |
|
944,954 | 2022-11-30 | 3 |
BEETHAM THOMAS W. SEE REMARKS |
|
19,897 | 2022-11-30 | 3 |
MAHONEY STEPHEN F. SEE REMARKS |
|
17,264 | 2022-11-30 | 2 |
STANTS KRISTEN CHIEF PEOPLE OFFICER |
|
20,264 | 2022-11-30 | 3 |
DEARDORF CAREN CHIEF COMMERCIAL OFFICER |
|
19,762 | 2022-11-30 | 3 |
|
0 | 2022-08-15 | 2 | |
HUMPHREY JEFFREY CHIEF MEDICAL OFFICER |
|
75,000 | 2022-08-01 | 1 |
OLSON LISA SEE REMARKS |
|
100,000 | 2022-08-01 | 1 |
NICHOLS DAVID WAYNE CHIEF TECHNICAL OFFICER |
|
75,000 | 2022-08-01 | 1 |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
20,000 | 2022-06-28 | 1 | |
|
4,100 | 2021-08-26 | 0 | |
|
18,188 | 2021-06-01 | 0 | |
|
No longer subject to file | 2021-02-11 | 0 | |
ZDRAVESKI ZORAN SEE REMARKS |
|
0 | 2021-02-11 | 0 |
DAVIS JOHN C. JR SEE REMARKS |
|
0 | 2021-02-11 | 0 |
DRISCOLL CINDY SEE REMARKS |
|
0 | 2020-10-01 | 0 |
ATLAS VENTURE OPPORTUNITY FUND I, L.P. |
|
1,250,000 | 2020-06-29 | 0 |
|
0 | 2020-06-05 | 0 | |
RYAN JASON SEE REMARKS |
|
0 | 2020-02-10 | 0 |
ISACSON CHRISTINA K. CHIEF BUSINESS OFFICER |
|
0 | 2020-02-10 | 0 |
COOKE MICHAEL P. CHIEF SCIENTIFIC OFFICER |
|
240,523 | 2019-12-02 | 0 |
|
4,117,125 | 2019-03-20 | 0 | |
|
No longer subject to file | 2018-06-25 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 22:15:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 21:45:05 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 21:15:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 20:45:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 20:15:05 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 19:45:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 19:15:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 18:45:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 18:15:03 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 17:45:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 17:15:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 16:45:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 16:15:03 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 15:45:03 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 15:15:03 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 14:45:05 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 14:15:04 UTC | -7.5293 | 12.5993 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 13:45:05 UTC | -6.5555 | 11.6255 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 13:15:03 UTC | -6.5555 | 11.6255 | 6500000 |
MAGENTA THERAPEUTICS INC MGTA | 2023-05-29 12:45:03 UTC | -6.5555 | 11.6255 | 6500000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Enhanced Index Plus Fund | MGTA | -17.0 shares, $-106.76 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | MGTA | -14.0 shares, $-87.92 | 2020-03-31 | N-PORT |